Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study.

What was studied

This study looked at children with B-cell leukemia who got stem cell transplants. It covered hypodiploid disease and BCR::ABL1 fusion. They were compared with children without these changes. The data came from the FORUM trial. 741 patients aged 4 and older took part. They were treated from 2013 to 2023.

What they found

Survival at 3 years did not differ significantly among the groups. Hypodiploid patients in second remission did worse. This was due to higher nonrelapse deaths, only in near-diploid cases. No such deaths occurred in severe hypodiploid cases given total body irradiation. Leftover disease at transplant predicted worse results in all groups. BCR::ABL1+ patients did well, even with leftover disease. Post-transplant TKI use improved event-free survival and cut relapse.

What it means for patients

The authors say the FORUM protocol gave comparable outcomes across the groups. They say TKI after transplant improved outcomes in BCR::ABL1+ disease.

Why it is not certain yet

Hypodiploid patients were hard to rescue after relapse. The abstract does not give group sizes. Subgroup results can be less firm than main results.

Source

Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study.

We restate facts from the source record in our own words. The original wording belongs to its publisher.